Form 424B5 ImmunityBio, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
ImmunityBio amends stock sale agreement to authorize $460M offering
December 29, 2025 6:04 AM ESTImmunityBio Inc. (NASDAQ: IBRX) amended its at-the-market stock offering agreement with Jefferies LLC on December 23, authorizing the sale of an additional $459.97 million in common stock shares.
The biotechnology company modified its existing Open Market Sale Agreement from April 2021, which allows for periodic... More
